Indications for RETROVIR IV:
HIV-1 infection, in combination with other antiretroviral agents. Prevention of maternal-fetal HIV-1 transmission.
Give by IV infusion over 1hr; use only until oral therapy can be given. 1mg/kg every 4hrs. Renal impairment (CrCL <15mL/min) or on dialysis: 1mg/kg every 6–8hrs. Prevention of maternal-fetal HIV or vertical transmission, severe anemia and/or neutropenia: see full labeling.
Vertical transmission: see full labeling.
Hematological toxicity. Myopathy. Lactic acidosis and severe hepatomegaly with steatosis.
Risk of hematologic toxicity/bone marrow suppression; monitor CBCs esp. in advanced HIV-1 disease; interrupt dose if anemia or neutropenia occurs. Myopathy with prolonged use. Suspend if lactic acidosis or pronounced hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Monitor for lipoatrophy; use alternatives if suspected. Severe renal impairment: reduce dose (see Adult). Hepatic impairment or cirrhosis: monitor for hematologic toxicity. Latex allergy (IV). Women. Obesity. Elderly. Pregnancy. Nursing mothers: not recommended.
Nucleoside analogue (reverse transcriptase inhibitor).
Avoid concomitant stavudine, doxorubicin, nucleoside analogues (eg, ribavirin). Increased hematologic toxicity with ganciclovir, interferon alpha, ribavirin, other bone marrow suppressants or cytotoxic drugs. Monitor for treatment-associated toxicities (eg, hepatic decompensation) with interferon alpha with or without ribavirin.
Headache, malaise, nausea, vomiting, anorexia; neutropenia, anemia, myopathy, lactic acidosis, severe hepatomegaly with steatosis, immune reconstitution syndrome, pancreatitis, lipoatrophy. Children: also fever, cough.
Tabs—contact supplier; Caps—100; Syrup—240mL; IV (20mL/vial)—1, 5